A Study to Investigate the Safety and Efficacy of Ricolinostat

Clinical trial NCT05229042 · COMPLETED

Trial details

NCT number: NCT05229042
Sponsor: Beijing 3E-Regenacy Pharmaceuticals Co., Ltd.
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Peripheral Nervous System Diseases

Start date: 2022-01-01
Primary completion: 2023-11-10
Enrollment: 10

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.